Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16644633 | 1.00 | PRCP (0.39) | PRCPBMPR1BPDGFRBKDRACVR1B | |
| SCHEMBL3697306 | 1.00 | PRCP (0.39) | PRCPBMPR1BPDGFRBKDRACVR1B | |
| SCHEMBL14258976 | 0.80 | BMPR1B (0.34) | BMPR1BPDGFRBKDRACVR1BTGFBR1 | |
| SCHEMBL1639188 | 0.80 | MAPT (0.43) | PRCPBMPR1BPDGFRBKDRACVR1B | |
| SCHEMBL29104079 | 0.80 | MAPT (0.43) | KDM1ATDP1HTR2AHTR2C | |
| SCHEMBL10563871 | 0.80 | PARP1 (0.35) | BMPR1BPDGFRBKDRACVR1BTGFBR1 | |
| SCHEMBL263978 | 0.80 | HTR3A (0.53) | PRCP | |
| SCHEMBL552751 | 0.80 | MAPT (0.43) | KDM1ATDP1HTR2AHTR2C | |
| SCHEMBL1673686 | 0.80 | HTR3A (0.53) | PRCP | |
| SCHEMBL9786119 | 0.80 | MAPT (0.43) | PRCPBMPR1BPDGFRBKDRACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1003236-B | Preparation method of 6, 7-disubstituted-1-cyclopropyl-1, 4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid | 拜尔公司 | 1989-02-08 | — | — | CN | claimed |
| US-4705788-A | Novel antibacterial 7-amino-1(substituted cyclopropyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1987-11-10 | — | — | US | claimed |
| CN-122036605-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2025264672-A1 | INHIBITORS OF MOBILIZED COLISTIN RESISTANCE ENZYME (MCR-1) AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | UNIV OREGON HEALTH & SCIENCE (US) | 2023-06-08 | — | — | US | disclosed |
| CN-115996908-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2023-04-21 | — | — | CN | disclosed |
| EP-4143163-A1 | ANTAGONISTS OF GPR39 PROTEIN | Oregon Health & Science University (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222858-A1 | ANTAGONISTS OF GPR39 PROTEIN | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-3177617-B1 | PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS LLC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-3057963-B1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-20170226067-A1 | PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| EP-0201829-A1 | 1-Aryl-4-quinolone-3-carboxylic acids | BAYER AG (DE) | 1986-11-20 | — | — | EP | disclosed |
| EP-0198192-A1 | 7-Amino-1-(subst.cyclopropyl)-1,4 -dihydro-4-oxo-quinoline carboxylic acids, method for their preparation, and antibacterial agents containing them | BAYER AG (DE) | 1986-10-22 | — | — | EP | disclosed |
| EP-0187376-A2 | 6,7-Disubstituted 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids | BAYER AG (DE) | 1986-07-16 | — | — | EP | disclosed |
| CN-86100126-A | 6, the two replacement-1-cyclopropyl of 7--1,4 dihydro-4-oxo-1, the preparation method and the application thereof of 8-naphthyridines-3-carboxylic acid | — | 1986-07-09 | — | — | CN | disclosed |
| US-4599334-A | 7-(3-aryl-1-piperazinyl)- and 7-(3-cyclohexyl-1-piperazinyl)-3-quinolonecarboxylic acid antibacterials | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-08 | — | — | US | disclosed |
| EP-0169993-A2 | 7-(3-Aryl-1-piperazinyl) and 7-(3-cyclohexyl-1-piperazinyl) 3-quinoline carboxylic acids | BAYER AG (DE) | 1986-02-05 | — | — | EP | disclosed |
| EP-0167763-A1 | 7-Amino-1-cyclopropyl-6,8-dihalo-1,4-dihydro-4-oxo-3-quinoline-carboxylic acids, process for their preparation and bactericidal agents containing them | BAYER AG (DE) | 1986-01-15 | — | — | EP | disclosed |
| EP-0164619-A1 | 2,4,5-Trihalo or 2,3,4,5-tetrahalo benzene derivatives and process for producing them | BAYER AG (DE) | 1985-12-18 | — | — | EP | disclosed |
| US-4166180-A | 2-ARYLPIPERAZINE DERIVATIVES AND THE PREPARATION THEREOF | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1979-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | GPR39, GPR139, GPR119 | PRCP 1700/4885BMPR1B 1704/4885PDGFRB 753/4885 |
| US-20170226067-A1 | PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | NR1H2, NR1H3, NR1I2 | PRCP 1647/4885BMPR1B 950/4885PDGFRB 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.